The new investment will support platform expansion, preclinical development and team growth as DNAmic advances toward clinical translation.
DNAmic today announced the successful closing of a financing round that will accelerate the development of its proprietary human protein-based delivery platform for in vivo gene and cell therapies.
The proceeds will be used to expand research and development activities, strengthen the company's scientific team, advance preclinical validation and continue building the technological infrastructure required for future clinical development.
The financing represents an important milestone in DNAmic's growth, reflecting investor confidence in the company's differentiated approach to therapeutic delivery and its long-term vision of developing a safe, modular and scalable platform built entirely from engineered human proteins.
Alfonso Fiz
CEO and CO-Founder DNAmic
The company will continue to pursue strategic collaborations and additional financing opportunities to expand the clinical applications of its technology.
DNAmic is a biotechnology company developing a next-generation delivery platform for in vivo gene and cell therapies. Built entirely from engineered human proteins, the company's proprietary bioND™ platform is designed to overcome the key limitations of current viral and non-viral delivery technologies by combining efficient intracellular delivery, programmable cargo encapsulation, and cell-specific targeting within a single modular system.
info@dnamic.bio
